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Abstract 
 Synthetic cathinones, colloquially referred to as “bath salts” are derivatives of 
the psychoactive alkaloid found in Catha edulis, cathinone. Mephedrone and 2,3-
methylenedioxypyrovalerone or MDPV are examples of these amphetamine-like 
psychostimulants. Its use has increased worldwide in past years, becoming a health 
and a legal problem.  
MDPV and mephedrone as drugs of abuse can induce drug addiction; a 
chronically relapsing disorder which is defined by a compulsion to take the drug and a 
loss of control in limiting intake. Here, within the context of neurobiology of drug 
addiction, mechanisms involved in the development of addiction, including molecular 
and cellular changes induced in the rewarding circuit after repeated exposure to drugs 
of abuse are described.  
 Animal behavioral paradigms are critical to study the reinforcing effects of 
drugs of abuse. In the present study, conditioned place preference (CPP) paradigm was 
used to study the reinforcing properties of MDPV in rats. Different doses of MDPV      
(1, 3, 5 mg/kg s.c.) showed a significant place preference compared with saline 
controls.  
Resum 
Les cathinones sintètiques, referides col·loquialment com a sals de bany són 
derivats de l’alcaloide psicoactiu, catinona, que es troba a la planta Catha edulis. La 
mefedrona i el 3,4-metilenedioxipirovalerona o MDPV són exemples d’aquests derivats 
amfetamínics. En els últims anys, la seva utilització s’ha vist incrementada a nivell 
mundial, fent que esdevinguin problemes legals i de la salut.  
L’MDPV i la mefedrona com a drogues d’abús poden induir una addicció: un 
trastorn crònic de recaigudes definit com un desig compulsiu per prendre la substància 
i una pèrdua del control per limitar la seva administració. Aquí, en el context de la 
neurobiologia de l’addició a drogues, es descriuen els mecanismes involucrats en el 
desenvolupament de l’addicció, incloent els canvis a nivell molecular i cel·lular 
2 
 
Neurobiology of drug addiction 
ocasionats al circuit de la recompensa després de l’administració repetida de drogues 
d’abús.  
Els paradigmes de comportament en animals són crítics per a l’estudi dels 
efectes reforçants de les drogues d’abús. En aquest estudi, fet en rates, es va utilitzar 
el paradigma de condicionament de preferència de lloc per estudiar les propietats 
reforçants de l’MPDV. Les diferents dosis (1, 3, 5 mg/kg s.c.) de MDPV van demostrar 
diferències significatives de preferència de lloc en comparació amb els animals control.  
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Integration of the three different scopes  
 This project is about the neurobiology of addiction (including an example of 
synthetic cathinone, MDPV) and animal behavioral paradigms. It involves three 
different scopes: pharmacology and therapeutics, physiology and physiopathology, 
and toxicology.  
As it will be described below, this project is divided in two parts: a bibliographic 
review and an experimental part. The experiment consists in carrying out a test, the 
conditioned place preference (CPP) paradigm in order to study the rewarding 
properties of a drug of abuse, in this case, 3,4-methylenedioxypyrovalerone or MDPV. 
This experimental part was developed in the Department of Pharmacology and 
Therapeutic Chemistry and this is why pharmacology and therapeutics is the main 
scope.  
Toxicology scope is shown in the description of synthetic cathinones, 
particularly MDPV and mephedrone. Both of them are novel recreational drugs and, as 
substances of abuse, are able to induce addiction. Addiction is a disorder quite 
common in our society and drugs of abuse are considered chemical substances that 
may harm user’s organisms.  
Finally, physiology and physiopathology scope is important to describe the 
circuits involved in addiction’s development. The rewarding circuit and its adaptations, 
molecular and cellular, due to exposure to drugs of abuse is described in the present 
study.  
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1. Introduction  
Drug abuse and addiction have negative consequences from people to the 
society. Drugs of abuse suppose a risk for humans due to the existence of a fast and 
uncontrollable transition from the research of new experiences and feelings, by 
consumers, to use and abuse of these substances, which create dependence and, in 
unfortunate occasions, can finish with overdose or toxicity for chronic use. In Europe, 
more than 1.6 billion new consumers appear each year.  
The market of illicit drugs can be considered just as dynamic as markets for 
legal products. Designer drugs are synthetic compounds developed to provide 
rewarding effects similar to illicit drugs of abuse such as amphetamines, cocaine, 
heroin or marijuana while avoiding existing legislative classification and penalty(1). 
Often they are just chemically modified at a single position of the original molecule. 
Illicit laboratories, due to the low purity of cocaine and 3,4-
methylendioxymethamphetamine (MDMA), or because of the successful efforts made 
by governments to prevent the diversion of precursors to manufacture MDMA(2),  
have realized the need of throwing to the market a new family of drugs of abuse 
known as “legal highs”.  Among these new classes of drugs are the synthetic 
cathinones.  
Synthetic cathinones were first developed for therapeutic purposes, mainly as 
antidepressants and anorectic agents, but promptly started being abused for their 
euphoric, stimulant and hallucinogenic effects(1)(3). Cathinone and cathine are 
alkaloids and the main natural cathinones present in the leaves of the Catha edulis 
plant, commonly known as khat.  Khat is a flowering evergreen slow-growing shrub or 
tree that grows wild in the Horn of Africa and in the Southwest Arabian Peninsula. 
Peter Forskal, a Swedish botanist, during an expedition to Egypt and Yemen in 1761-
1763 described the khat plant. It was identified as a member of the family 
Celastraceae(3).  
For centuries, the chewing of fresh khat leaves has been a tradition in local 
communities for their gratifying stimulant effects. In Yemen, khat chewing is widely 
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practiced on a daily basis, at the so-called khat sessions, where men chat for several 
hours, usually after work(3).  
The most widely abused synthetic cathinones are mephedrone, methylone and 
3,4-methylenedioxyprovalerone or MDPV. All of them are derivatives of cathinone 
which is an alkaloid and has a similar structure to amphetamine(1). 
Synthetic cathinones are a ring-substituted cathinone closely related to 
phenethylamine family, differing only by a keto functional group attached at the beta 
carbon on the amino alkyl chain linked to the phenyl ring. This is why they are also 
known as β-keto amphetamines.   
 
 
 
 
 
 
 
 
 
The backbone of mephedrone, methylone and MDPV is phenethylamine with a ketone 
group at the β-carbon position. Mephedrone is methylated on the amine group, like 
methcathinone, and on the aromatic ring of its backbone. For this reason mephedrone 
is also known as 4-methylmethcathinone.  Methylone is also methylated on the amine 
group of β-ketophenethylamine backbone, but has a methylenedioxy ring attached to 
the aromatic ring, forming a structure close to MDMA. Methylone due to its structure 
is also entitled 3,4-methylendioxymethcathinone. MDPV has a methylenedioxy ring 
attached to the aromatic ring of the β-ketophenethylamine backbone and a 
Figure 1. Representation of the structure of cathinone, amphetamine and their derivatives 
compounds.  
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pyrrolidinyl ring and propane attached to α-carbon, instead of a methyl group, forming 
a structure close to pyrovalerone(1)(Fig. 1). MDPV due to its pyrrolidine ring and the 
tertiary amino group is a more lipophilic and more potent monoamine uptake inhibitor 
than other cathinone derivatives. Its structure creates a less polar molecule more able 
to cross the blood-brain barrier. Moreover, its nitrogen atom forming the tertiary 
amino group is the responsible of its high solubility in organic solvent(4).  
Synthesis of mephedrone was first described in 1929 as stimulant for central 
nervous system (CNS) by Saem de Burnaga Sanchez(5) and MDPV was synthesized by 
Boehringer Ingelheim and patented in 1969(6). However, its abuse was not reported 
until the early 2000s. Methylone, in turn, is a more recent analogue and was patented 
in 1996(7). After their discovery, the synthetic cathinones were ignored until their 
abuse as a legal alternative to MDMA was reported on internet drug websites in 2003.  
These synthetic cathinones mentioned above are the most common 
compounds found within “bath salts”, “plant food” and “research chemicals”, slang 
terms used by manufacturers of these synthetic cathinones in order to circumvent 
legal repercussions(8). Mephedrone is the most widely abused synthetic cathinone 
within Europe, whereas MDPV is the most frequently abused within the USA(1).  
In 2011, the DEA (Drug Enforcement Administration) placed mephedrone and 
MDPV and their salts, isomers, and salts of isomers on Schedule I status of the 
Controlled Substance Act (CSA)(9). This scheduling makes them illegal to manufacture, 
distribute, possess, import, and export. 
Nonetheless, legal regulation of synthetic cathinones is rather difficult to attain 
success, since they are easily replaced by novel compounds after minor structure 
modifications. Consequently, for each drug that gets banned, new and more powerful 
analogues will reach the licit drug markets.  
Bath salts contain one or a mixture of synthetic cathinones and are sold under 
several inexplicit brand names, including “Bloom”, “Bubbles”, “Meow Meow”, “Blue 
Silk”, “Ivory Wave”, “Purple Wave” and “Vanilla Sky” and labelled as “not for human 
consumption”(3)(9)(10)(11). Bath salts are purchased locally at convenience stores and 
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at head- or smartshops, or conveniently over Internet suppliers, being readily 
accessible, affordable, and technically legal(3). Head shop is a retail outlet specialized 
in paraphernalia used for consumption of cannabis, tobacco, and legal highs.   
Synthetic cathinones are generally sold in form of a white or yellowish amorphous or 
crystalline powder and are usually found as 200 mg to 10 g packets, or in capsules; 
tablets are more uncommon(3). Producers and sellers claim to provide synthetic 
cathinones with over 99% purity. However, analyses of seized and purchased products 
demonstrate purity of around 95% with adulterants including benzocaine, lidocaine, 
caffeine, piperazines and paracetamol(1).  
These compounds are used via multiple routes including nasal insufflations, oral 
ingestion, rectal insertion with mucosal absorption, gingival application, inhalation, 
intramuscular and intravenous, being nasal insufflations and oral ingestion the most 
common ways(9)(12). Nasal insufflations are done by “snorting” and more specifically 
by “keying” which consists in dipping a key in powder and then being insufflated(9). 
Many nasal users experiment agitation because of nasal irritation, leading them to 
change to oral administration. Oral ingestion is done by swallowing capsules or 
“bombing” which consists in wrapping the powder in cigarette paper and swallowing 
it(13).  
Reports of “typical” doses for mephedrone are 100 to 200 mg orally, with onset 
of effects around 30 to 45 minutes and a duration of 2 to 5 hours(12)(14). MDPV 
seems to present more potent effects, causing effects in 15 to 30 minutes after dosing 
with a typical oral dose of 10 to 15 mg. The psychoactive effects may last from 2 to 7 
hours(14). When MDPV is insufflated with a common dose of 5 to 11 mg, effects are 
observed in 5 to 20 minutes and they may last from 2 to 3.5 hours. Independently of 
administration’s route, after coming down from MDPV there are several hours of 
increased physical and mental stimulation, during which it is difficult to sleep(15).  
Studies on the metabolism have shown that mephedrone is N-demethylated to 
a primary amine, followed by reduction of the ketone moieties to alcohols, 
subsequently; the tolyl group is oxidized to the corresponding alcohol. Finally, some of 
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the alcohols are then conjugated via sulfation or glucuronidation and excreted in the 
urine(16). Metabolism of MDPV begins with the opening of the methylenedioxy ring, 
followed by demethylation leading to a catechol ring which is subsequently methylated 
by catechol-O-methyltransferase (COMT). β-keto moiety is also reduced to an alcohol. 
Finally, some of the metabolites are then conjugated via sulfation or glucuronidation 
and excreted in the urine, too(17).  
Clinical effects reported with mephedrone and MDVP use are similar to 
sympathomimetic toxicity. Specific case reports and Internet descriptions by users 
denote effects very similar to cocaine, methamphetamine, and ecstasy(9). Reported 
subjective effects include mental and physical stimulation, euphoria, increased energy, 
increased productivity and motivation, empathy, talkativeness, heightened alertness, 
and sexual arousal(10)(15)(18). Users of synthetic cathinones have also exhibited 
sweating, palpitations, nausea, vomiting, loss of appetite, headache, tightened jaw 
muscles, muscle twitching, grinding teeth (trismus and bruxism), dizziness, vertigo, 
nystagmus, and impaired short-term memory(15)(18)(19). Other neurologic and 
psychiatric effects like self-mutilation, suicide attempts, and persistent paranoid 
psychosis have also been described with both acute and chronic use(14). In fact, 
agitation that can range from mild to severe psychosis is the most commonly reported 
complication.  
Synthetic cathinones were shown to exert their effects by interacting with 
plasma membrane monoamine transporters, specifically dopamine transporter (DAT), 
noradrenaline transporter (NET), and serotonin transporter (SERT), resulting in an 
increased concentration of these biogenic amines in the synaptic cleft(20)(21)(22)(23). 
However, different affinities toward these transporters are observed between 
synthetic cathinones. Drugs due to their interactions with monoamine membrane 
transporters can be classified as substrates like amphetamines or blockers like cocaine. 
Mephedrone acts as a non-selective inhibitor for all catecholamine transporters and 
also as serotonin releaser, similar to MDMA(22)(23)(24). Contrarily, MDPV acts as a 
pure monoamine-selective transporter blocker, with high potency for DAT and NET 
(50-fold and 10-fold more potent than cocaine), but weak for SERT (10-fold less potent 
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than cocaine) due to the presence of 3,4-methylenedioxy ring-substitution(21)(25). 
High concentrations of DA in brain are crucial for addiction and rewarding effects after 
drugs administration.   
Finally, evidences from animal studies support the reinforcing properties and 
abuse liability of synthetic cathinones, namely mephedrone and MDPV, confirmed by 
their ability to elicit self-administration patterns in rats. Examining the ability of MDPV 
to support intravenous self-administration (IVSA) and to lower thresholds for 
intracranial self-stimulation (ICSS) in rats, Watterson et al. demonstrated that the 
synthetic cathinone MDPV possesses potent reinforcing properties and suggests a high 
degree of abuse potential in humans(26). Using Conditioned Place Preference (CPP) 
model, a powerful and direct method to investigate abuse potential, Karlsson et al. 
concluded that mephedrone and MDPV produce CPP suggesting addictive 
properties(27).  
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2. Objectives  
The overall aim of the present study is to get close to drug addiction, and in 
order to achieve it, the following study is divided in two parts. The first one is a 
bibliographic review in which the main aim is to describe drug addiction, considering 
factors which may have influence on drug abuse and mechanisms and pathways 
involved in addiction. Due to drugs of abuse present different risk of abuse in humans 
and this risk can be predicted using tests based on behavioral paradigms in animals, 
description of various animal behavioral paradigms will be addressed in this study.  
The second part is an experiment and its aim is to investigate if the synthetic 
cathinone MDPV induces conditioned place preference in rats. There is not any 
published study on MDPV and CPP in rats, whereas there are on MDPV in mice and on 
mephedrone in both, rats and mice.  
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3. Materials and methods  
3.1 Animals and treatment groups 
 Males Sprague-Dawley rats (Harlan, Spain) aged 5 weeks and weighing 130 to 
160 g were used. Animals were housed two per cage under normal indoor 
temperature and humidity, and maintained on 12 h light/dark cycle from 8:00 am to 
8:00 pm. They had free access to food (standard laboratory diet, PANLAB SL, 
Barcelona, Spain) and drinking water.  
All experimental procedures for the use of animals in this study were approved 
by the Animal Ethics Committee of the University of Barcelona under the supervision 
of the Autonomous Government of Catalonia and following the guidelines of the 
European Communities Council (86/609/EEC). Efforts were made to minimize suffering 
and reduce the number of animals used.  
Rats (n=28) were assigned to one of four treatment groups: saline (saline s.c. + 
saline s.c.), MDPV 1 mg/kg (saline s.c. + MDPV 1 mg/kg s.c.), MDPV 3 mg/kg (saline s.c. 
+ MDPV 3 mg/kg s.c.), MDPV 5 mg/kg (saline s.c. + MDPV 5 mg/kg s.c.). Before 
experimentation, all of the animals received two habituation sessions (48 and 24 hours 
before testing) in order to reduce the novelty and stress linked to handling and 
injection.  
3.2 Drugs 
 Pure MDPV hydrochloride was synthesized and characterized in the 
Department of Pharmacology and Therapeutic Chemistry of Faculty of Pharmacy 
following the protocol described by Aarde et al., (2013)(28) with little modifications. 
MDPV solutions for injection were prepared in sterile 0.9% sodium chloride (saline) 
immediately before administration.  
3.3 Literature research 
 In order to conduct a search of articles as extensively as possible, literature 
explorations were performed using the following electronic database: PubMed. The 
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key words used were: addiction, 3,4-methylenedioxypyrovalerone OR MDPV, 
mephedrone OR 4-methylmethcathinone, CPP, self-administration, self-stimulation, 
synthetic cathinones. Key words were used singly and in combination.  
3.4 Conditioned Place Preference (CPP) paradigm 
 The place conditioning protocol used was non-biased and closed to the one 
Ciudad-Roberts et al., (2013)(29) followed.  The apparatus was composed of three 
distinct compartments separated by manually operated doors. The central 
compartment or corridor measured 27 x 10 x 25 cm (w x d x h) and its function 
consisted in communicating the two pairing sides. The pairing compartments had the 
same size 20 x 20 x 25 (w x d x h) but different appearance. One compartment had 
black and white chequered walls with a smooth and shiny floor, whereas the other had 
white and light blue painted walls and rough floor.  
 CPP was performed in three phases: preconditioning, conditioning, and test. 
During preconditioning phase, day 1, animals were placed in the middle of the corridor 
and had free access and move among the three compartments (corridor and both 
pairing sides) for 20 minutes. The time spent in each compartment was recorded by 
computerized monitoring software (Smart 3, Panlab SL, Barcelona, Spain). Animals 
were expected not to demonstrate preference for any of the pairing compartments.  
 On days 2, 4, 6 and 8 of conditioning phase, rats were treated with MDPV (1, 3 
and 5 mg/kg, s.c.), or saline, 20 minutes before being placed in one of the two 
compartment for 30 minutes.  On days 3, 5, 7 and 9 of the conditioning phase, animals 
received saline and were placed in the opposite compartment respect where they had 
received the drug the day before. Animals were exposed to only one compartment per 
day and treatments were counterbalanced to ensure that some animals received 
MDPV in one of the two pairing compartments and others in the other one. Control 
animals received saline every day.  
 The test phase, day 10, was conducted identically to the preconditioning phase. 
Animals were placed in the middle of the corridor and had free access to move among 
the three compartments for 20 minutes. On test day, animals did not receive the 
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substance. The time spent in each compartment was measured and a preference score 
was expressed in seconds. This score was calculated as the difference between the 
times spent in the drug-paired compartment in the test phase minus the time spent in 
the preconditioning phase.  
3.5 Statistical analysis  
All data are expressed as means ± standard error of the mean (S.E.M.). Differences 
between groups were compared using one-way analysis of variance (ANOVA). For all 
comparisons, p values < 0,05 were considered statistically significant. Significant 
differences were then analyzed by Tukey’s post hoc test for multiple means 
comparisons.  
All data were kindly given by PhD Patrícia Muñoz (Department of Pharmacology and 
Therapeutic Chemistry of Faculty of Pharmacy). 
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4. Results  
4.1 Results from bibliographic research  
 Addiction is the quintessential complex disorder. It is a process that manifests 
itself in the uncontrollable, compulsive drug seeking and use, and that persists even in 
spite of negative health and social consequences(30). So, it is defined specifically as a 
compulsive pattern of drug-seeking and drug-taking behavior that takes place at the 
expense of most other activities. It is believed that the development of addiction 
involves a transition from casual to compulsive patterns of drug use.  
 Addictive substances induce pleasant states such as euphoria in the initiation 
phase. Continued use induces adaptive changes in the central nervous system that 
lead to tolerance, physical dependence, sensitization, craving, and relapse(31).  
 Theories of addiction have been developed from neurobiologic evidence and 
data from studies of learning behavior and memory mechanisms. Koob and Le 
Moal(32) proposed that when a drug is administered, the organism tries to counteract 
the drug’s effects through a vicious circle in which the hedonic set point –point at 
which pleasure is achieved- is continually changing in response to the administration of 
the drug.  
Robinson and Berridge’s(33) explanation for addiction is that drugs are first taken 
because they are pleasant, but with repeated drug use homeostatic neuroadaptations 
lead to tolerance and dependence. Then, unpleasant withdrawal symptoms appear 
after the cessation of use. Compulsive drug taking is maintained to avoid unpleasant 
withdrawal symptoms. So, addictive drugs are first taken to achieve pleasant drugs 
“highs”, and after addiction, to escape withdrawals “lows”.  
Robinson and Berridge also emphasized the dissociation between the incentive value 
of the drug called “wanting” and its pleasurable or hedonic effects “liking”(33). They 
added that the brain system involved in the reward mechanism becomes 
hypersensitized to direct effects of the drug and also to the stimuli associated that are 
not directly attributable to the drug. In fact, environmental stimuli also known as cues, 
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associated with drug use itself can induce a conditioned response, withdrawal or 
craving, in the absence of the drug. The hypersensitisation causes pathologic wanting 
or craving, independently of the presence of withdrawal symptoms and leads to 
compulsive drug-seeking and drug-taking behavior(33).  
4.1.1 Opponent process theory of addiction 
Solomon and colleagues(34) described a theory named the opponent process 
and based on the pleasure/withdrawal view of addiction. This theory describes 
processes of addiction in graphic ways that allow the transition to addiction to be 
visualized.  
 
 
 
 
 
 
 
 
The opponent process theory describes that pleasant doses of a drug activate a 
dose-dependent a-process in brain reward circuits, which in turns triggers activation of 
a negative or opponent b-process. This process serves to restore homeostasis and 
bring brain states back to normal. The summation of a- and b- process creates the final 
experienced state felt by the person. This state is named A-state when the summed 
effect is pleasantly drug-like what means that a-process surpasses b-process. It is 
called B-state when it is unpleasantly drug-opposite, what means that b-process 
surpasses a-process(33)(34)(Fig. 2).  
Figure 2. Opponent process model of addiction. Initially A-state is large, 
followed by a small B-state. However, with repeated drug use, the opponent 
b-process increases in magnitude and duration, leading to a large B-state(33). 
16 
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The euphoric high of the drug A-state is directly caused by a-process. B-process 
is manifested first as mild decay of the drug’s high after the initial peak. If the drug is 
taken again, the b-process is strengthened and manifest as tolerance to drug euphoria, 
so A-state is reduced. In this state, if the user wants to repeat previous experiences, he 
or she has to increase the dose. Finally, unpleasant withdrawal is caused when drug 
effects wear off because the b-process is posited to last longer than the a-process, so 
the person feels the B-state. Only the b-process is posited to change with repeated 
drug-taking. In fact, it grows in magnitude and in duration, leading to an experience 
dominated by the unpleasant symptoms associated with withdrawal. Even though, 
prolonged abstinence from the drug would decay the b-process, and the ability to 
reactivate it would return to normal(33)(34).  
4.1.2 Factors influencing drug abuse and dependence 
There are some factors that may influence on drug abuse and dependence -a 
cluster of cognitive, behavioral, and physiological symptoms indicating that a person is 
going to continue using a substance despite having clinically significant substance-
related problems(31) : 
• Pharmacologic and physicochemical properties of drugs: pharmacologic and 
physicochemical properties of a drug influence in how a drug is consumed. 
Liposolubility, for example, facilitates the passage of a drug through the blood-
brain barrier (BBB). Contrarily, water solubility promotes the injection of the 
drug. If the drug is volatile, it will be consumed by inhalation in vapour form, 
whereas presents resistance to heat, it will be smoked.  
Rapid onset and intensity of effects are characteristics that increase the 
potential for abuse. Moreover, when a drug has a short half-life it produces 
more abrupt and intense syndromes of withdrawal -constellation of signs and 
symptoms that follows the abrupt discontinuation or reduction in the use of a 
substance or after blockage of the actions of a substance with antagonist- than 
does a long half-life.  
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• Personality and psychiatric disorders: personal traits and mental disorders are 
main conditioning factors in drug addiction. Risk-taking or novelty-seeking 
features favour the use of addictive drugs. Mental disorders like schizophrenia, 
bipolar disorder, depression, and attention-deficit-hyperactivity disorder, are 
associated with an increased risk of abuse.  
• Genetic factors: genetic factors which influence the metabolism and the effects 
of drugs contribute to the risk of addiction.  
• Environmental factors:  these factors are characteristics in a person’s 
surroundings that increase their likelihood of becoming addicted to drugs. The 
community, family, school, and friends are environments that may have 
influence on risk of addiction(35).  
4.1.3 Neuropsychopharmacology of reward 
 A reward is defined as an incentive stimulus that positively reinforces behavior, 
that is, it increases the probability of the behavior’s occurrence due to its pleasure-
related effects. Rewards are positive reinforcers, while aversive events, such as electric 
shocks that elicit an avoidance response, are negative reinforcers and are called 
punishers. In fact, addictive drugs can act as positive reinforcers when they produce 
euphoria or as negative reinforcers when they alleviate withdrawal’s symptoms or 
dysphoria(36).  
Natural rewards such as food, drink, and sex and drug rewards stimulate the 
release of dopamine from neurons of the presynaptic ventral tegmental area (VTA) 
into the nucleus accumbens (NAc), causing euphoria and reinforcement of the 
behavior. Despite both of them have the same mechanism, in natural rewards there is 
a rapid adaptive change, or habituation, after a few experiences, and the 
unexpectedness of the reward seems to be more important in the initial response. In 
drug rewards, there is not this habituation, and each dose of the drug stimulates the 
release of dopamine.  
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Numerous brain regions and neurotransmitters are involved in the reward 
circuit. However, the most studied among them in relation to drug addiction are 
mesocorticolimbic and nigrostriatal dopamine systems:  
a) The mesolimbic circuit includes projections from cell bodies of the VTA to 
NAc (Fig. 3). This pathway is known to induce neuronal and behavioral 
sensitizations associated with rewarding and reward-associated stimuli. 
Contextual stimuli are represented in different limbic areas, basolateral 
amygdala and hippocampus, whose glutamatergic projections ascend to the 
NAc via the medial prefrontal cortex. This pathway has been implicated in 
memory and conditioned responses linked to craving and the emotional 
and motivational changes of the withdrawal syndrome(36).  
In order to connect this pathway with the opponent process theory of 
addiction, Koob and colleagues(32) suggested that the positive a-process is 
caused by activation of mesolimbic dopamine projections to the NAc and 
amydala that mediate the acute reinforcing effects of drugs. Repeated drug 
use, induces tolerance or downregulation in the mesolimbic dopamine 
system, decreasing the drug A-state. 
b) The mesocortical projections ascend from the VTA to the prefrontal cortex, 
orbitofrontal cortex and anterior cingulated. This circuit is involved in the 
conscious experience of the effects of drugs, drug craving, and the 
compulsion to take drugs. It is an essential component of the emotional 
response network that ensures normal cognitive functioning, in particular 
working memory and decision making.  
c) The nigrostriatal projections connect from the substantia nigra to the dorsal 
striatum (caudate-putamen), where dopamine is associated with the 
initiation and execution of habitual behavior, although its role in reward has 
also been shown.  
Projections from the γ-aminobutiric acid (GABA) neurons of the NAc to the 
VTA and prefrontal cortex interact with the circuits described above (Fig. 3).   
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4.1.4 The leading role of dopamine 
 Dopamine is a neurotransmitter associated with the reinforcing effects of drugs 
of abuse and may have a key role in triggering the neurobiological changes associated 
with addiction. Despite the fact that each drug of abuse binds to different initial 
protein target, all of them increase the extracellular concentration of dopamine in the 
NAc(38). For example, stimulants increase dopaminergic transmission in the NAc, 
directly. Opiates increase the same transmission, but indirectly. They inhibit GABAergic 
interneurons in the VTA, which desinhibits VTA dopamine neurons. Opiates also act on 
opioid receptors on NAc neurons, but in this case directly. Nicotine seems to stimulate 
directly nicotinic cholinergic receptors on VTA dopamine neurons and indirectly 
receptors on glutamatergic nerve terminals that innervate the dopamine cells. Alcohol, 
in its turn, promotes GABAA receptors function what may inhibit GABAergic terminals 
in VTA like opiates. Alcohol also may inhibit glutamatergic terminals that innervate NAc 
neurons(39)(Fig. 4).  
 
 
Figure 3. A simplified schematic of VTA-NAc reward circuit in the rodent brain. The primary reward circuit 
includes dopaminergic projections from the VTA to the NAc. There are also GABAergic projections from 
the NAc to the VTA. The glutamatergic inputs to VTA control aspects of reward-related perception and 
memory(37).  
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Dopamine is responsible of diversity effects because modulates different brain 
regions (limbic, cortical, and striatal). For example it mediates the hedonic 
consequences of a reinforcing stimulus, promotes associative learning about the 
stimulus or anticipates its rewarding effects(40). It has been described that when there 
is a substantial decrease in dopamine levels in NAc, the withdrawal syndrome is 
experimented(41). 
 There are five different subtypes of dopamine receptors, but they are classified 
only in two groups: D1-like receptors group which includes subtypes D1 and D5, and 
D2-like receptors group, which contains D2, D3 and D4. All of them are G-protein-
coupled receptors. D1-like receptors activate adenylyl cyclase (AC), whereas D2-like 
receptors inhibit the enzyme(31). G proteins are trimeric structures composed of two 
functional units: α subunit that catalyzes GTPase activity (converts GTP to GDP) and β-γ 
subunits. Both subunits can activate or inhibit enzymes such as adenylyl cyclase or 
phospholipase C that synthesize cyclic adenosine monophosphate (cAMP), inositol 
triphospahte and diacylglycerol. These second messengers can activate protein 
kinases, which phosphorylate and regulate ion channels. In addition, these protein 
Figure 4. Highly simplified scheme of converging acute action of drugs of abuse on the VTA-NAc.(39)  
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kinases induce pharmacological effects and produce changes in transcription factors 
such as CREB (cAMP-responsive element-binding protein) and ΔFosB(31).  
4.1.5 Common circuit-level adaptations  
 All drugs increase dopaminergic transmission to the NAc after acute 
administration. After chronic exposure to drugs of abuse, some adaptations in 
dopamine function are also produced(39). Despite the fact that there are many 
different drugs of abuse with their dosing regimens and routes of administration, a 
common adaptation scheme can be described.  
Chronic exposure to any drug of abuse impairs dopamine system, which can be seen as 
a homeostatic response to repeated drug activation of the system, in other words, 
tolerance. Moreover, after chronic exposure, baseline levels of dopamine function are 
reduced, and normal rewarding stimuli may be less effective. In addition, chronic drug 
exposure seems to sensitize the dopamine system, with greater increases in 
dopaminergic transmission occurring in response to the drug in question and to drug-
associated cues. Sensitization is one of the neurobiologic mechanisms involved in 
craving and relapse(31).   
 Another adaptation to chronic exposure to drugs of abuse is cortical 
“hipofrontality”, which means that there is a reduced baseline activity of several 
regions of frontal cortex, such as prefrontal cortex, anterior cingulated cortex, and 
orbitofrontal cortex. This brain region, frontal cortex, controls executive function, 
including working, memory, attention and behavioral inhibition. It is also important in 
controlling individual’s response to environmental stimuli.  
It has been demonstrated that chronic exposure to drugs of abuse causes complex 
changes in these frontal cortical regions and their glutamatergic outputs, which are 
implicated in the profound impulsivity and compulsivity that characterizes a state of 
addiction(38)(42).  
  Chronic drug states are also associated with changes in corticotropin releasing 
factor (CRF) system. When a withdrawal syndrome appears due to any drug of abuse, 
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it leads to activation of CRF-containing neurons in the amygdale(43). These neurons 
are involved in fear and other aversive states and innervate many forebrain and 
brainstem regions. It is known that activation of these neurons during drug withdrawal 
mediates the negative emotional symptoms, many of the somatic symptoms that 
occur upon drug withdrawal, and may contribute to drug craving and relapse(39).  
In addition, CRF can be considered as an example of “opponent process”, which means 
that it serves to counteract all changes induced in the brain by drugs and drives 
withdrawal symptoms when drug’s administration is discontinued(42).  
CREB, a transcription factor is responsible of CRF gene regulation. Therefore, the 
hyperactivity of central CRF pathways upon precipitation of drug withdrawal which 
reflects molecular adaptations in amygdala neurons can be produced by CREB’s 
induction(32).       
4.1.6 Common cellular and molecular adaptations  
 Chronic exposure to drugs of abuse causes numerous common adaptations at 
the cellular and molecular level in the VTA-NAc and other brain reward regions. There 
are too many adaptations to describe here comprehensively; so, only those related to 
CREB and ΔFosB will be presented.  
 After chronic exposure to many drugs of abuse, including amphetamines, so do 
MDPV and mephedrone, transcription factor CREB is activated. The rise of CREB in the 
NAc and, to a lesser extent, in the VTA, has been linked to reduced drug-induced 
reinforcement. In fact, overexpression of CREB in the accumbens inhibits the 
rewarding effects of pshychoestimulants, mu opioids and biological rewards. Alcohol 
and nicotine, by contrast, reduce CREB activity, at least in the NAc(39).  
The main steps involved in CREB-mediated gene transcription include 
dimerization, binding at response elements in DNA, and phosphorylation(43). CREB is a 
transcription factor that binds as dimmers to the cAMP-response element (CRE), a 
specialized stretch of DNA that contains the consensus nucleotide sequence 
TGACGTCA. CRE sites are found within the regulatory region of numerous genes; if a 
23 
 
Neurobiology of drug addiction 
promoter contains CREs, then it could be subject to regulation by CREB, depending on 
several tissue-specific factors(44).  
 
 
 
 
 
  
 
As described in point 4.1.4, when dopamine D1-like receptors are stimulated, 
AC is activated and accumulation of cAMP increases which causes liberation of the 
catalytic subunits of cAMP-dpendent protein kinase (PKA). The free catalytic subunit 
enters to the cell nucleus and phosphorylates CREB. Phosphorylation of CREB activates 
a cascade of events that involves recruitment of associated proteins such as CREB-
binding protein (CBP) and assembly of a larger transcriptional complex.  
There are various phosphorylation sites on the CREB protein that differentially regulate 
CREB activity. For example, PKA, Ca2+/calmodulin dependent kinase (CaMK)IV and 
MAPK-activated ribosomal S6 kinases (RSKs), each phosphorylate CREB at serine 133, 
which stimulates the recruitment of CBP and leads to the activation of gene 
transcription. Contrarily, CaMKII phosphorylates CREB at serine 142, which promotes 
the dissociation of the CREB dimer and thereby reduces gene transcription(44).  
Increased CREB function, after exposure to drugs of abuse, appears to cause 
tolerance and dependence, adaptations commonly associated with the development 
and maintenance of addictive behaviors(44). Homer, c-Fos, ΔFosB, NAC-1, and 
preprodynorphin are some examples of genes implicated in addiction and their 
transcription is promoted by CREB(45) (Fig. 5). Preprodynorphin, NAC-1, and Homer, 
Figure 5. Dopamine D1 receptor-dependent signaling in 
the NAc hypothesized to underlie the transition from social 
use to enduring vulnerability to relapse(45).  
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contribute to the compensatory effect increasing CREB to reduce the value of drug 
reward. Increased dynorphin, for example, inhibits the activity of dopamine cells and 
presynaptic dopamine release. So, increased dynorphin expression is associated with 
aversive or depressive-like effects such as those that often accompany drug 
withdrawal(44).  
The increase in many transcriptional regulators and immediate early genes, 
such as cFos, Arc, and Homer, decreases after repeated exposure. In contrast, ΔFosB 
accumulates in dopamine-terminal fields in the cortex and striatum. This accumulation 
occurs in response to chronic administration of drugs of abuse, and in response to 
repeated biologically motivating stimuli. There is considerable evidence that ΔFosB 
accumulation within NAc neurons contributes to state of sensitization(46). Nestler et 
al., (2005) (39) hypothesized that induction of ΔFosB mediates many shared aspects of 
drug and natural addictions by regulating a set of common target genes. 
ΔFosB is a member of the Fos family of transcription factors, which dimerize 
with a member of the Jun family to form activator protein-1 (AP-1) transcription factor 
complexes. These complexes then bind to AP-1 sites which are consensus sequence, 
TGAC/GTCA present in the regulatory regions of many genes(41). 
Some of the genes regulated by ΔFosB may be compensatory and serve to limit drug 
reinforcement, and maybe drug-seeking, like genes regulated by CREB. For example, 
the induction of Cdk5, cyclin-dependent kinase-5, phosphorylates the dopamine-
regulated phophatase DARPP-32, thereby preventing its phosphorylation and 
activation by PKA. Cdk5 promotes nerve cell growth and mediates(47) an enduring 
increase in dendritic spine density in accumbens spiny cells during extended 
abstinence from chronic psychostimulant administration(45).  
On the other hand, the induction of other genes by ΔFosB promotes drug 
reward and many studies indicate that overexpression of ΔFosB increases drug reward. 
The induction of GluR2 in the shell of the accumbens is one of the ΔFosB gene 
regulation examples that would promote drug reward. GluR2 is a particular AMPA 
25 
 
Neurobiology of drug addiction 
glutamate receptor subunit and its expression is increased in NAc upon overexpression 
of ΔFosB.  
The induction of GluR2 reduces the electrical excitability of NAc neurons, as GluR2-
containing AMPA channels show reduced overall conductance and reduced Ca2+ 
permeability. This reduction could mediate enhanced reward mechanisms by, for 
example, making the neurons more sensitive to inhibition by subsequent drug 
exposure(41)(46). Another example is suppression of dynorphin expression which  
contribute to the enhancement of reward(45)(46) .  
4.1.6.1 Role of the BDNF-TrkB signalling in dopaminergic neurons exposed to 
addictive drugs 
 Another dopamine-dependent change in protein synthesis that appears 
particularly important in establishing physiological as well as drug-induced 
neuroplasticity is a rise in brain-derived neurotrophic factor (BDNF)(45).  Neurotrophic 
factors like BDNF that bind to the tropomyosin-related kinase B (TrkB) receptor were 
shown to be important in the development of the central nervous system and in 
shaping neuronal morphology of dopamine neurons and other brain circuits(48).  
BDNF expression can be increased by psychostimulants in VTA dopaminergic neurons. 
These increases consolidate and persist over time during abstinence and during 
extinction of drug self-administration and in craving incubation paradigms(48).  
 The main intracellular pathways activated by BDNF-TrkB signalling are the MEK-
ERK or MAPK-ERK, the PI3K-Akt-mTORC1, the PLCγ-DAG-PKC/Ca2+, and NFkB pathways, 
all involved in cell survival and growth(49). These pathways are not only activated by 
BDNF, but also by G-protein coupled receptors, as described above. Collo et al., (2013) 
demonstrated that phosphorylation in both MEK-ERK and Akt-mTORC1 pathways is 
critical for structural plasticity, because pretreatments with selective inhibitors for ERK, 
PI3K and mTORC1 block the increase of soma size and dendritic arborization produced 
by psychostimulants(50).  
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Structural plasticity includes hiperplastic and hypoplastic phenomena, which 
mean, the increase or decrease of number and size of morphologically defined 
components of the neuron. Both hyperplastic and hypoplastic phenomena have been 
produced in the brain reward circuit by drugs of abuse. Psychostimulants are 
associated with hyperplastic phenomena, whereas opiates with hypoplastic(48). 
Morphine, for example, reduces BDNF expression in VTA neurons and low BDNF levels 
are associated with reduced soma size. Moreover, after local infusion with BDNF, 
normalizes soma size(49). In contrast, stimulants increase dendritic branching and 
spine number in VTA dopamine neurons and NAc medium spiny neurons. This 
structural plasticity is associated with activation of ERK in both regions and with 
activation of PLCγ in the NAc(49).  
4.1.7 Neurobiology, animal behavioral paradigms  
 Various animal behavioral paradigms have been used to study the neuronal 
substrates involved in addiction, especially euphoria and rewarding effects. Self-
stimulation, self-administration and conditioned place preference are examples of 
animal behavioral paradigms(31). For some drugs, such as synthetic cathinones, the 
risk of abuse in humans can be predicted using tests based on behavioral paradigms in 
animals.  
4.1.7.1 Intracranial self-stimulation (ICSS) 
 Intracranial self-stimulation is one family of experimental procedures that has 
been used to assess abuse liability of stimulants and other drugs. In ICSS, subjects are 
trained to lever press for pulses of brain stimulation delivered via microelectrodes 
implanted in brain regions such as VTA, VTA’s projections to NAc, prefrontal cortex, 
and hypothalamus. ICSS produces a positive reward when a threshold of stimulation is 
achieved(35).  
The animal, after having learnt that when it presses a lever a positive reward’s 
effect is produced, will continue pressing the lever looking for the rewarding effects. 
However, ICSS can be modified with administration of drugs of abuse that are 
expected to produce a positive reinforcement.  When a drug of abuse that produces 
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Figure 6.  Representation of ICSS paradigm. Animals are trained to press 
a lever to receive intracranial current in brain-rewarding loci(31).  
positive reinforcement is administered, the number of lever’s taps will be reduced 
because there is a reduction in stimulation’s threshold. The animal has to press less 
times the lever to achieve the same positive reward’s effects due to the drug.  
 
 
 
 
 
 
So, the paradigm consists on administrating a drug of abuse to a subject, and 
observing if the threshold of stimulation is modified or not. If the threshold is reduced, 
it will indicate that the drug is a positive reinforcer.  
4.1.7.2 Intravenous self-administration (IVSA) 
 This paradigm consists in conditioning an animal to self-administrate a drug of 
abuse intravenously with a catheter when a lever is pressed. The catheter is placed 
into the jugular vein and is connected to an infusion pump which has the drug’s 
solution: when the animal presses the lever, a switch of a programme, which is 
connected to the pump and regulates the drug’s flow, is activated and the drug 
administrated. There are different kinds of administration, being the intermittent, 
which means that the drug is only administrated after a particular number of taps on 
the lever, the most common(35). 
This test is conducted in a specific chamber equipped with two levers located on one 
wall and a food pellet receptacle placed between them. At the beginning of the test 
procedures, animals have restricted diet and they have to learn that pressing one 
lever, a sucrose pellet is delivered. During this training, the other lever is inactive. 
Approximately 24 hours after sucrose training, acquisition phase in “fixed ratio” (FR1) 
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begins. Fixed ratio means that the animal has to press only once the lever to get the 
drug’s dose or the sucrose pellet. This phase consists on daily sessions of 2 hours self-
administration. In this case, a particular volume of drug of abuse is administrated 
through the catheter when the other lever, not the one which delivers sucrose pellet, 
is pressed(26). 
 
 
 
 
 
Following ten days of 2 hours IVSA sessions, a progressive ratio (PR) schedule is 
conducted to study the reinforcement efficacy of the drug. During the PR tests, the 
number of lever presses required to get a single infusion is determined by an equation 
described by Richardson and Roberts, 1996 (26): responses per                             
reinforce delivery = 5 x e(injection number – 0.2) -5.  In PR experiments, the break point or 
final point is also valued. This point is a reflex of the motivation generated by the 
addictive substance. The break point is considered to be achieved when animals do not 
emit any lever presses for 2 hours.  
4.1.7.3 Conditioned place preference (CPP) 
 The conditioned place preference paradigm is a standard preclinical behavioral 
model used to study the rewarding and aversive effects of drugs. The basic 
characteristic of this test is the association of a particular environment with drug 
treatment, followed by the association of a different environment with the absence of 
the drug(51).  
A large number of designs and apparatuses are used in this model, but a 
common variation consists of a three-compartment chamber with the outer 
compartments designed to have different characteristics. To achieve this difference, 
Figure 7. Representation of IVSA. Animals are trained to press a lever 
to obtain a drug or saline administration(31).  
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walls can be painted with different colours, black vs white, flooring can be different as 
well, horizontal grid vs. cross-grid.  
The central compartment has not any special characteristics and lets the animal move 
from one compartment to the other one; is like a corridor. This compartment is not 
paired with the drug. Moreover, between compartments there are gates which can be 
opened or closed in order to allow the animal to pass freely or to hold the animal in a 
specific compartment.  
 The paradigm consists of a training phase and a test phase. During the training 
phase, an injection of a drug with rewarding or aversive properties is administered to 
an animal and then is placed into one of the outer compartments for several minutes. 
On the following day, the animals are injected with the drug’s vehicle and placed into 
the opposite compartment. Usually, these daily sessions alternate between drug and 
vehicle for 2 or 3 days each.  
After training phase, the test session is conducted. In this session all gates are opened 
so the animal can move freely around all the apparatuses. This session consists of 
placing the animal in the middle of the central compartment and recording the time 
the animal spends in each compartment during the session.  
 A conditioned place preference (CPP) is found if the animal spends more time 
in the drug-paired compartment versus the vehicle-paired compartment. Contrarily, if 
the animal spends more time in the vehicle-paired compartment versus the drug-
paired compartment, then is considered a conditioned place aversion (CPA).  
As described, the conditioned place preference and self-administration 
paradigms measure the rewarding properties of drugs. However, some differences 
exist between them. First, although CPP and IVSA are sensitive to the rewarding effects 
of many of the same drugs, some drugs produce CPP but may not be self-administered, 
while others are self-administered but do not produce CPP. Second, the mechanisms 
that mediate drug-induced CPP and self-administration of a drug may be different. 
Third, there is an important difference between these two models in methodological 
procedures; IVSA requires surgical implantation of a catheter. Finally, IVSA studies 
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have been conducted in monkeys, rats, mice, and pigeons, whereas CPP studies have 
only been conducted in rats and mice(51). 
 
 
 
 
 
 
 
 
 
 
 
4.2 Results from experimental procedure  
4.2.1 3,4-methylenedioxyprovalerone (MDPV) and Conditioned Place 
Preference 
 The CPP paradigm was used to study the effect of different doses on the 
rewarding properties of MDPV.  
During pre-conditioning phase rats were placed in the middle of the corridor and were 
allowed free access to the entire apparatus for 20 minutes. The relative time spent in 
each compartment was calculated. Rats that spent more than 60 % of the time in one 
compartment, so less than 40% in the other one were excluded from test.  
Figure 8. Representation of CPP. A positively reinforcing 
effect of the drug is apparent if the mouse spends more 
time in the environment in which the drug was 
administered(31).  
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Time spent in each compartment was recorded during preconditioning phase 
and in test. The preference score was calculated by subtracting time in the drug-paired 
compartment during the pretest from time spent in the drug-paired compartment 
during the test. Means ± SEM of relative time in drug-paired compartment are shown 
in Table 1. 
 
 
Significant treatment effect was found between groups when the preference 
score was compared [F3,24 = 10,28 ;  p < 0,001]. Post hoc analysis revealed that 1, 3 and 
5 mg/kg MDPV showed a significant place preference when compared with saline-
treatment controls. These results are shown below (Fig. 9).  
 
  
 
 
 
 
 
 
 
Treatment Relative Time Pretest (PT) Relative Time Test (T) Preference Score (T-PT) 
Saline 650,26 ± 36,27 543,84 ± 76,94 -176,06 ± 60,61 
MDPV 1mg/kg 567,35 ± 62,03 727,97 ± 46,70 160,62 ± 23,18 
MDPV 3mg/kg 577,82 ± 32,77 785,46 ± 36,15 207,64 ± 57,89 
MDPV 5mg/kg 590,32 ± 34,29 735,27 ± 63,70 144,94 ± 66,55 
Figure 9. Effects of different doses of MDPV in the CPP assay in rats. 
Data are expressed as preference score. Values are means ± S.E.M. 
**p<0,01 ***p<0,001 compared to saline; n=7 in all groups.  
Table 1. Relative time spent in drug-paired compartment during the pretest and during the test. The 
preference score is also shown. Values are means ± S.E.M.   
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5. Discussion 
 Drug addiction is a chronically relapsing disorder that has been characterized by 
compulsion to seek and take the drug, loss of control in limiting intake, and emergence 
of a negative emotional state, such as dysphoria, anxiety, reflecting a motivational 
withdrawal syndrome when access to the drug is prevented(52). Drug use is initiated 
primarily to obtain the excitatory actions of addictive drugs on brain reward 
system(53).  
Drug addiction has aspects of both impulse control disorders and compulsive 
disorders. First ones are characterized by an increasing sense of tension or arousal 
before committing an impulsive act and are largely associated with positive 
reinforcement mechanisms. On the other hand, compulsive disorders are 
characterized by anxiety and stress before committing a compulsive repetitive 
behavior and are largely associated with negative reinforcement mechanisms and 
automaticity. Therefore, collapsing the cycle of impulsivity and compulsivity results on 
a composite addiction cycle composed of three stages: binge/intoxication, 
withdrawal/negative effects, preoccupation/anticipation, in which impulsivity usually 
dominates at the early stages and impulsivity combined with compulsivity at the later 
stages(52).  
The development of addiction involves a transition from casual, in fact drug use 
is initiated primarily to obtain the excitatory actions of addictive drugs on brain reward 
system, to compulsive patterns of drug use. This transition to addiction is accompanied 
by many drug-induced changes in the brain and associated changes in pshychological 
functions(33).  
Most of these drug-induced changes, cellular and molecular, have been shown 
throughout diverse neuronal populations within the brain reward circuit. For example, 
the transcription factor CREB has been implicated in addiction. Activation of CREB in 
the nucleus accumbens and several other regions by drugs of abuse mediates certain 
aspects of drug addiction(44). Some other genes, are transcripted as a result of CREB 
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binding to DNA, as ΔFosB, Cdk5, GluR2, dynorphin and Bdnf, whose proteins ultimate 
the adaptation to drug exposition.  
As described above, ICSS, IVSA and CPP are the most common animal 
behavioral paradigms used to study the abuse potential of a substance. Watterson et 
al., (2012) evaluated the abuse potential of MDPV by assessing its ability to support 
IVSA and to lower thresholds for ICSS in rats(26).  
They chose IVSA method due to the high degree correspondence between 
drugs that can have addictive potential in humans and drugs that function as 
reinforcers in IVSA procedures in animals. Their study revealed a positive relationship 
between MDPV doses and reinforce efficacy. This relationship was demonstrated 
during PR testing, and breakpoints for MDPV reinforcement at the lowest dose 
(0,1mg/kg) tested were similar to those for the same those of methamphetamine, a 
drug known to exhibit addictive properties.  
 When a substance produces lowering of ICSS threshold is generally accepted to 
be due to the facilitation of brain reward functioning, providing a direct measure of the 
hedonic and rewarding properties of drugs of abuse. In addition, nearly all abused 
stimulants including cocaine, amphetamine and methamphetamine lower ICSS 
threshold. Watterson et al., (2012) results revealed that MDPV lowers ICSS threshold 
across a wide range of doses compared with the vehicle.  
 To our knowledge, there were not published any results of which were the 
effects of MDPV on conditioned place preference in rats. Karlsson et al., (2014) 
demonstrated that MDPV produce a significant preference shift at all doses tested 
(0.5, 2, 5, 10, 20 mg/kg) compared with the control mice(27). In fact, their CPP data 
showed that MDPV is more or equally potent than amphetamine in their tested 
interval.  
Our results revealed that MDPV induces CPP at all doses tested (1, 3, 5 mg/kg) 
compared with the control rats. Doses tested are very low compared to those used 
with cocaine (20 mg/kg) to achieve same effects. In addition, there is no linear 
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relationship between dose and effect, but it is known the lack of a CPP dose-response 
function for a lot of reinforcers, such as cocaine.  
So, taken together these results it is suggested that MDPV possesses a strong 
potential for compulsive use and can thereby be a risk of abuse in humans.  
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6. Conclusions  
• Drug addiction is a chronic, relapsing disorder in which compulsive drug-seeking 
and drug-taking behavior persists despite serious negative consequences.  
• Each drug of abuse, despite their many distinct actions in the brain, converges 
in producing some common actions. Prominent among these actions is the 
activation of mesolimbic dopamine system also known as the rewarding circuit.  
• The development of addiction involves a transition from casual to compulsive 
patterns of use. After repeated exposure to a drug of abuse, molecular and 
cellular changes are progressively being induced.  
• There are two transcription factors, in particular, that have been implicated in 
addiction: CREB and ΔFosB.  
• ICSS, IVSA and CPP are three of the most common animal behavioral paradigms 
used to study the abuse potential of a substance and its rewarding properties.  
• MDPV induces CPP at lower doses compared to cocaine. So, MDPV addictive 
properties are higher than cocaine’s. 
• MDPV as an example of synthetic cathinones possesses a strong potential for 
compulsive use and can be a risk of abuse in humans. MDPV is an 
amphetamine’s derivative and is currently under legal control in some states.  
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